Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin
Authors:
- 1 November 2017
- journal article
- Published by Elsevier in Experimental Cell Research
- Vol. 360 (2) , 281-291
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Hebei Province (H2016206243)
- Hebei Provincial 2016 government-funded clinical talents training and basic research projects (361005)
- Hebei College Natural Science top talent project (BJ2016037)
This publication has 51 references indexed in Scilit:
- Imaging of diabetic boneEndocrine, 2017
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone ActionCell Metabolism, 2013
- Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone MetabolismFrontiers in Endocrinology, 2013
- Safety of Antidiabetic Therapies on BoneClinical & Translational Metabolism, 2012
- Pleiotropic Actions of the Incretin Hormones2010
- Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic statesRegulatory Peptides, 2010
- Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant StatesCalcified Tissue International, 2009
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- The Burden of Mortality Attributable to DiabetesDiabetes Care, 2005
- Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor.Endocrinology, 1993